Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [31] Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
    Hwang, Young Sol
    Kim, Hwa Jung
    Kim, Jisun
    Chung, Il Yong
    Ko, Beom Seok
    Kim, Hee Jeong
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei-Hyun
    Lee, Sae Byul
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [32] Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study
    Adkins, ES
    Sawin, R
    Gerbing, RB
    London, WB
    Matthay, KK
    Haase, GM
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) : 931 - 936
  • [33] Enrollment on upfront high-risk neuroblastoma trials by race, ethnicity, and poverty status: A report from the Children's Oncology Group
    Umaretiya, Puja J.
    Naranjo, Arlene
    Zhang, Fan F.
    Irwin, Meredith S.
    DuBois, Steven G.
    Bagatell, Rochelle
    Bona, Kira
    PEDIATRIC BLOOD & CANCER, 2024, 71 (07)
  • [34] Outcome of High-Risk Stage 3 Neuroblastoma With Myeloablative Therapy and 13-cis-Retinoic Acid: A Report From the Children's Oncology Group
    Park, Julie R.
    Villablanca, Judith G.
    London, Wendy B.
    Gerbing, Robert B.
    Haas-Kogan, Daphne
    Adkins, E. Stanton
    Attiyeh, Edward F.
    Maris, John M.
    Seeger, Robert C.
    Reynolds, C. Patrick
    Matthay, Katherine K.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (01) : 44 - 50
  • [35] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Alzahrani, Ali S.
    Mukhtar, Noha
    ENDOCRINE, 2022, 78 (03) : 531 - 542
  • [36] Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group
    Aksoylar, Serap
    Varan, Ali
    Vergin, Canan
    Hazar, Volkan
    Akici, Ferhan
    Dagdemir, Ayhan
    Buyukavci, Mustafa
    Kebudi, Rejin
    Kurucu, Nilgun
    Sevinir, Betul
    Unal, Emel
    Vural, Sema
    Guler, Elif
    Apak, Hilmi
    Oniz, Haldun
    Karadeniz, Ceyda
    Canpolat, Cengiz
    Anak, Sema
    Ilhan, Inci
    Ince, Dilek
    Cecen, Emre
    Olgun, Nur
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2017, 13 (02) : 284 - 290
  • [37] Development and validation of a risk stratification nomogram for predicting prognosis in bone metastatic breast cancer A population-based study
    Hou, Niuniu
    Yi, Jun
    Wang, Zhe
    Yang, Lu
    Wu, Ying
    Huang, Meiling
    Hou, Guangdong
    Ling, Rui
    MEDICINE, 2021, 100 (06) : E24751
  • [38] A safety and feasibility trial of 131I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
    Weiss, Brian D.
    Yanik, Gregory
    Naranjo, Arlene
    Zhang, Fan F.
    Fitzgerald, Wendy
    Shulkin, Barry L.
    Parisi, Marguerite T.
    Russell, Heidi
    Grupp, Stephan
    Pater, Luke
    Mattei, Peter
    Mosse, Yael
    Lai, Hollie A.
    Jarzembowski, Jason A.
    Shimada, Hiroyuki
    Villablanca, Judith G.
    Giller, Roger
    Bagatell, Rochelle
    Park, Julie R.
    Matthay, Katherine K.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [39] Development and validation of an interpretable nomogram for predicting the risk of the prolonged postoperative length of stay for tuberculous spondylitis: a novel approach for risk stratification
    Parhat Yasin
    Haopeng Luan
    Cong Peng
    Xinghua Song
    BMC Musculoskeletal Disorders, 26 (1)
  • [40] Development and validation of a postoperative nomogram for predicting overall survival after endoscopic surgical management of olfactory neuroblastoma
    Yang, Jingyi
    Song, Xiaole
    Lai, Yuting
    Zhao, Weidong
    Zhou, Jiaying
    Liu, Quan
    Li, Wanpeng
    Zhang, Huankang
    Wang, Huan
    Shi, Peng
    Yu, Hongmeng
    Sun, Xicai
    Wang, Dehui
    ECLINICALMEDICINE, 2020, 29-30